Trials / Terminated
TerminatedNCT05949632
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB099280 | Administered as specified in the treatment arm description |
| DRUG | axitinib | Administered as specified in the treatment arm description |
Timeline
- Start date
- 2024-04-16
- Primary completion
- 2025-06-06
- Completion
- 2025-06-06
- First posted
- 2023-07-18
- Last updated
- 2025-08-03
Locations
6 sites across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05949632. Inclusion in this directory is not an endorsement.